| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tartaric acid disodium dihydrate targets acid phosphatase as an inhibitor. It also targets tubulin, increasing the rate of colchicine binding to tubulin. The compound has vasodilatory and antihypertensive effects. It can be used as a flavoring agent and antioxidant in foods and beverages. The compound is also used in laser frequency doubling and optical limiting applications.
|
|---|---|
| ln Vitro |
In vitro, Tartaric acid disodium dihydrate is an acid phosphatase inhibitor. It increases the rate of colchicine binding to tubulin. The compound is used as a buffer in molecular biology and cell culture applications. It demonstrates vasodilatory and antihypertensive effects in cell-based assays. The compound is soluble in water at 90 mg/mL (ultrasonic).
|
| ln Vivo |
In vivo, Tartaric acid disodium dihydrate is orally active and has vasodilatory and antihypertensive effects. It can be used as a flavoring agent and antioxidant in foods and beverages. The compound is isolated from grapes. Its antihypertensive effects have been demonstrated in preclinical studies. Further in vivo studies are ongoing to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for Tartaric acid disodium dihydrate involve measuring acid phosphatase inhibition. Acid phosphatase activity is assessed using a suitable substrate such as p-nitrophenyl phosphate. The compound is added at varying concentrations, and inhibition is quantified. Tubulin binding assays measure the rate of colchicine binding to tubulin in the presence of the compound. Vasodilatory effects are assessed in vascular smooth muscle cell models. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Tartaric acid disodium dihydrate are conducted in various cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Acid phosphatase activity is measured in cell lysates. Vasodilatory effects are assessed in vascular smooth muscle cells. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Tartaric acid disodium dihydrate in vivo studies are conducted in animal models of hypertension. Animals are treated with the compound via oral administration. Blood pressure is monitored using appropriate techniques. Vasodilatory and antihypertensive effects are assessed. For metabolic studies, the compound's effects on acid phosphatase activity are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Tartaric acid disodium dihydrate (MW 232.10 g/mol, C4H10Na2O8) is soluble in water at 90 mg/mL (ultrasonic). It appears as a white crystalline powder. The compound is an orally active weak organic acid. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. The compound is used as a buffer and in molecular biology applications.
|
| Toxicity/Toxicokinetics |
Tartaric acid disodium dihydrate is generally recognized as safe as a food additive and buffer component. The compound is an orally active weak organic acid found in grapes. It has vasodilatory and antihypertensive effects. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Sodium L-tartrate is the disodium salt of L-tartaric acid, an organosodium salt. It is used as a food emulsifier. It contains L-tartrate (2-).
See also: Sodium tartrate dihydrate (note moved to). Tartaric acid disodium dihydrate (Sodium tartrate dibasic dihydrate) is an orally active weak organic acid isolated from grapes. It is an acid phosphatase inhibitor that increases colchicine binding to tubulin. The compound has vasodilatory and antihypertensive effects and is used as a flavoring agent and antioxidant in foods and beverages. Its molecular formula is C4H10Na2O8 with a molecular weight of 232.10 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C4H8NA2O8
|
|---|---|
| Molecular Weight |
230.0811
|
| Exact Mass |
193.98
|
| CAS # |
6106-24-7
|
| Related CAS # |
L-Tartaric acid;87-69-4
|
| PubChem CID |
162637
|
| Appearance |
White to off-white solid powder
|
| Density |
1,82 g/cm3
|
| Boiling Point |
399.3ºC at 760 mmHg
|
| Melting Point |
150°C -2H₂O
|
| Flash Point |
209.4ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
123
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[Na+].[Na+]
|
| InChi Key |
HELHAJAZNSDZJO-OLXYHTOASA-L
|
| InChi Code |
InChI=1S/C4H6O6.2Na/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);;/q;2*+1/p-2/t1-,2-;;/m1../s1
|
| Chemical Name |
disodium;(2R,3R)-2,3-dihydroxybutanedioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~430.85 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (86.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3463 mL | 21.7316 mL | 43.4631 mL | |
| 5 mM | 0.8693 mL | 4.3463 mL | 8.6926 mL | |
| 10 mM | 0.4346 mL | 2.1732 mL | 4.3463 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
